Compare PHAT & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAT | CGBD |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | 2500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 826.2M |
| IPO Year | 2019 | N/A |
| Metric | PHAT | CGBD |
|---|---|---|
| Price | $11.61 | $10.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 8 |
| Target Price | ★ $19.83 | $12.92 |
| AVG Volume (30 Days) | ★ 1.4M | 598.3K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 14.42% |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $93.04 | $3.74 |
| Revenue Next Year | $58.91 | $1.80 |
| P/E Ratio | ★ N/A | $10.36 |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $3.70 | $10.64 |
| 52 Week High | $18.31 | $14.32 |
| Indicator | PHAT | CGBD |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 39.63 |
| Support Level | $11.04 | $10.68 |
| Resistance Level | $13.03 | $12.17 |
| Average True Range (ATR) | 0.79 | 0.29 |
| MACD | -0.13 | -0.10 |
| Stochastic Oscillator | 20.09 | 12.48 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.